Abstract
Background. Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, comprises a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. NASH is associated with an increased risk of hepatocellular carcinoma (HCC) and cardiometabolic disease. Insulin resistance (IR) is the underlying pathogenic mechanism for NAFLD, the presence of which in turn, is a strong predictor for the development of metabolic disorders. Hence, therapy of NAFLD with insulin-sensitizing drugs (ISDs) should ideally improve the key hepatic histological changes (steatosis, inflammation and fibrosis), but should also reduce cardiometabolic and cancer risk.
Objectives. In this review, the rationale for the use of ISDs and the evidence for their efficacy are detailed. In particular, the mechanism of action, potential for use, limitations and untoward effects of metformin and thiazolidinediones are systematically reviewed. Further, we discuss novel ISDs that may have potential clinical utility in NAFLD.
Results and Conclusion. Despite the theoretical prediction that ISDs might have beneficial effects on disease outcomes, evidence that ISDs are able to alter the natural history of NAFLD are presently not available. The exploration of novel strategies exploiting “nonconventional” ISDs is encouraged.
Current Pharmaceutical Design
Title:Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Volume: 19 Issue: 29
Author(s): Lucia Carulli, Mauro Maurantonio, Lionel Hebbard, Enrica Baldelli, Paola Loria and Jacob George
Affiliation:
Abstract: Background. Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, comprises a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. NASH is associated with an increased risk of hepatocellular carcinoma (HCC) and cardiometabolic disease. Insulin resistance (IR) is the underlying pathogenic mechanism for NAFLD, the presence of which in turn, is a strong predictor for the development of metabolic disorders. Hence, therapy of NAFLD with insulin-sensitizing drugs (ISDs) should ideally improve the key hepatic histological changes (steatosis, inflammation and fibrosis), but should also reduce cardiometabolic and cancer risk.
Objectives. In this review, the rationale for the use of ISDs and the evidence for their efficacy are detailed. In particular, the mechanism of action, potential for use, limitations and untoward effects of metformin and thiazolidinediones are systematically reviewed. Further, we discuss novel ISDs that may have potential clinical utility in NAFLD.
Results and Conclusion. Despite the theoretical prediction that ISDs might have beneficial effects on disease outcomes, evidence that ISDs are able to alter the natural history of NAFLD are presently not available. The exploration of novel strategies exploiting “nonconventional” ISDs is encouraged.
Export Options
About this article
Cite this article as:
Carulli Lucia, Maurantonio Mauro, Hebbard Lionel, Baldelli Enrica, Loria Paola and George Jacob, Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD, Current Pharmaceutical Design 2013; 19 (29) . https://dx.doi.org/10.2174/1381612811319290009
DOI https://dx.doi.org/10.2174/1381612811319290009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Docking Studies for Multi-Target Drugs
Current Drug Targets Mediterranean Diet and Risk of Dementia
Current Alzheimer Research Towards an Experimental and Systems Biology Framework for Cancer Cell Therapeutics
Current Bioinformatics Genetic Studies of Type 2 Diabetes in South Asians: A Systematic Overview
Current Diabetes Reviews Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload
Infectious Disorders - Drug Targets Flavonoids Isolated from Rumex aquaticus Exhibit Neuroprotective and Neurorestorative Properties by Enhancing Neurite Outgrowth and Synaptophysin
CNS & Neurological Disorders - Drug Targets Nitric Oxide Synthases and Their Natural Inhibitors
Current Enzyme Inhibition Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Current Drug Safety Antioxidant Activity and Chemical Components as Potential Anticancer Agents in the Olive Leaf (Olea europaea L. cv Leccino.) Decoction
Anti-Cancer Agents in Medicinal Chemistry Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Sevoflurane in Intraoperative and Postoperative Cardiac Surgery Patients. Our Experience in Intensive Care Unit with Sevoflurane Sedation
Current Pharmaceutical Design Understanding the Language of Vitamin C
Current Nutrition & Food Science Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice
Current Vascular Pharmacology Sleep Apnea: an Underestimated Cause of Resistant Hypertension
Current Hypertension Reviews Editorial [ Angiogenesis: A Promising Treatment Option for Peripheral Arterial Disease ]
Current Vascular Pharmacology